Can I Take Calcium With Crestor (Rosuvastatin)?

The Short Answer: Calcium and Crestor Do Not Directly Interfere

There is no pharmacokinetic interaction between calcium carbonate or calcium citrate and rosuvastatin. Rosuvastatin is absorbed via organic anion transporting polypeptide (OATP) transporters in the gut wall and liver, not through the divalent metal chelation pathway that allows calcium to block drugs like tetracycline antibiotics or levothyroxine. Clinical pharmacology data in the Crestor prescribing information confirm that rosuvastatin's primary absorption mechanism is transporter-mediated, not pH- or mineral-dependent chelation.

What you do need to think about:

• The dose of supplemental calcium you are taking
• Other medications in your regimen that calcium does block (levothyroxine, bisphosphonates, certain antibiotics)
• Your cardiovascular risk profile, particularly relevant if you are postmenopausal
• Whether food-source calcium versus supplement calcium is a better fit for your situation

How Rosuvastatin Works, and Where Calcium Does (and Does Not) Fit In

Rosuvastatin's absorption pathway

Rosuvastatin is a hydrophilic HMG-CoA reductase inhibitor. Unlike lipophilic statins such as atorvastatin or simvastatin, it relies heavily on OATP1B1 and OATP1B3 hepatic uptake transporters to reach its site of action in the liver. Calcium ions do not meaningfully inhibit or induce these transporters at physiological or supplemental doses.

What calcium does interact with

Calcium carbonate (the most common supplement form) requires stomach acid for dissolution and can transiently raise gastric pH. This matters for:

• Levothyroxine: calcium can reduce thyroid hormone absorption by up to 39% if taken within 4 hours. Many women on statins are also hypothyroid, making this the most clinically important interaction in your pill routine, not the Crestor itself.
• Bisphosphonates (alendronate, risedronate): calcium blocks bisphosphonate absorption almost completely if taken together. Women taking a bisphosphonate for osteoporosis alongside a statin need to separate calcium by at least 30-60 minutes after the bisphosphonate dose.
• Certain quinolone antibiotics and doxycycline: calcium chelates these. This is periodic rather than a daily concern, but worth knowing.

Rosuvastatin is not on that list.

The pharmacodynamic question

Pharmacodynamics is where things get more nuanced for women. Rosuvastatin lowers LDL-cholesterol, reduces inflammation, and has pleiotropic effects on vascular endothelium. Calcium supplementation, at doses above food intake, has been associated in some meta-analyses with modest increases in cardiovascular event risk. A 2016 JAMA Internal Medicine meta-analysis of 4 trials found that supplemental calcium at doses greater than 1,000 mg per day was associated with a statistically significant increase in myocardial infarction risk (RR 1.22, 95% CI 1.07-1.39) in community-dwelling adults not selected for deficiency.

This does not mean calcium cancels out your statin. It means that taking 1,500 mg of calcium supplements daily on top of a statin-protected cardiovascular system is not a consequence-free choice. Total calcium from food plus supplements matters more than the supplement dose alone.

Calcium Needs Across a Woman's Life: Why This Matters More Than You Think

Calcium requirements and the reasons women take both calcium and rosuvastatin overlap heavily in the perimenopausal and postmenopausal decades. Here is how the picture changes by life stage.

Reproductive years (roughly ages 18-40)

Statin use is less common in this group, though women with familial hypercholesterolemia, PCOS-related dyslipidemia, or lupus-associated cardiovascular risk may be prescribed rosuvastatin before menopause. The National Osteoporosis Foundation recommends 1,000 mg of calcium daily from all sources for women in this age group. Food sources alone can often meet this target. Supplementation is generally limited to women with documented deficiency, dairy-free diets, or malabsorption.

PCOS specifically increases atherogenic dyslipidemia risk. A 2013 Journal of Clinical Endocrinology and Metabolism analysis found that women with PCOS have significantly higher triglycerides and lower HDL compared to BMI-matched controls, which sometimes prompts statin initiation even in the third or fourth decade. Calcium supplementation in PCOS has its own data: a 2015 randomized trial in Clinical Nutrition found that 1,000 mg calcium per day alongside 50,000 IU vitamin D every two weeks improved fasting glucose and insulin resistance in women with PCOS over 8 weeks. That is a reason to take both, not a reason to avoid either.

Perimenopause (typically ages 45-55)

Estrogen decline accelerates bone turnover. The International Menopause Society 2023 position statement notes that women lose 1-3% of bone mass per year in the first 5 years after the final menstrual period. Calcium and vitamin D together are first-line adjuncts for skeletal protection. Simultaneously, LDL-cholesterol tends to rise after the final menstrual period as estrogen's lipid-modifying effect disappears, which is a common trigger for statin initiation.

This is the life stage where most women will first find themselves holding both a rosuvastatin prescription and a calcium supplement. The interaction concern is not between those two agents; it is about whether the calcium dose is appropriate given total dietary intake and whether levothyroxine is also in the mix.

Postmenopause

The North American Menopause Society (NAMS) 2021 position statement on nonhormonal management recommends that postmenopausal women obtain 1,200 mg of calcium daily, preferably from food, with supplementation reserved for the gap between dietary intake and that target. Women who can get 800 mg from food need only a 400 mg supplement, not an additional 1,000-1,200 mg tablet. Overshoot increases the cardiovascular signal from the JAMA Internal Medicine meta-analysis cited above without adding bone benefit.

A DEXA scan result showing osteopenia or osteoporosis often prompts prescribers to add a bisphosphonate. If you are taking rosuvastatin plus alendronate plus calcium plus levothyroxine, the sequencing of those four agents matters enormously. Calcium and levothyroxine must be separated. Calcium and alendronate must be separated. Rosuvastatin and alendronate have no clinically meaningful interaction with each other. Rosuvastatin and calcium have no clinically meaningful interaction with each other. Your pharmacist or clinician should map out a timed schedule for your full regimen.

Pregnancy and Lactation: Rosuvastatin Is Contraindicated

Rosuvastatin must not be taken during pregnancy. This is a hard stop.

The FDA classifies rosuvastatin as Pregnancy Category X. The Crestor prescribing label states explicitly that rosuvastatin is contraindicated in pregnancy because cholesterol and its biosynthetic intermediates are required for fetal development. Animal studies showed skeletal malformations at clinically relevant exposures; human data are insufficient to quantify the exact risk, but the theoretical harm is significant enough that no benefit-risk calculation favors use in pregnancy.

What to do if you become pregnant while on rosuvastatin

Stop rosuvastatin immediately and contact your prescribing clinician. Lipid management during pregnancy relies on dietary modification and, in severe familial hypercholesterolemia cases, LDL apheresis.

Lactation

The prescribing label advises against breastfeeding while taking rosuvastatin because it is unknown whether rosuvastatin passes into human milk and because of the potential for serious adverse reactions in a nursing infant. Women who are lactating and require statin therapy should discuss alternatives with their clinician; most guidelines recommend deferring statin therapy until breastfeeding is complete.

Calcium in pregnancy and lactation

Calcium is safe and necessary during pregnancy. ACOG recommends 1,000 mg of calcium daily during pregnancy, and 1,000-1,300 mg during lactation depending on age. Calcium supplementation starting at 20 weeks reduces preeclampsia risk in women with low baseline calcium intake, per a Cochrane review that analyzed 27 trials involving more than 18,000 women. In short: if you are pregnant, stop the rosuvastatin and continue the calcium.

Contraception requirement

Because rosuvastatin is teratogenic, women of reproductive potential taking it should use effective contraception. This is especially relevant in the perimenopause, where irregular cycles can create ambiguity about fertile status. Discuss contraception explicitly with your clinician if you are on rosuvastatin and have not yet reached 12 consecutive months of amenorrhea.

Cardiovascular Risk in Women: The Statin-Calcium Picture

Women have historically been underrepresented in cardiovascular trials. The JUPITER trial (2008), which established rosuvastatin 20 mg for primary prevention in people with elevated hsCRP, enrolled approximately 38% women. Subgroup analyses suggested the relative risk reduction in major cardiovascular events was consistent in women (HR 0.54, 95% CI 0.37-0.80), though the absolute event rate in women in the primary-prevention population was lower than in men, a point the trial authors noted.

The calcium-cardiovascular debate has a similar evidence gap in women. Most calcium meta-analyses have been dominated by postmenopausal women because that is who takes calcium supplements most consistently. The 2016 JAMA Internal Medicine analysis found that the cardiovascular signal was present specifically for supplemental calcium, not dietary calcium. Getting calcium from yogurt, cheese, sardines, leafy greens, and fortified plant milks does not carry the same risk signal as taking an additional 1,000-1,200 mg tablet on top of an adequate diet.

The practical implication: if your rosuvastatin is already protecting your cardiovascular system, do not unnecessarily add a large calcium supplement dose that might work in the opposite direction. Target the gap between your diet and your daily requirement, not a fixed round number.

Women-Specific Conditions That Affect Both Calcium and Statin Use

PCOS

Women with PCOS have higher rates of dyslipidemia, insulin resistance, and subclinical atherosclerosis. Statin use in PCOS is supported by several small randomized trials. A 2016 meta-analysis in Human Reproduction Update found that statins reduced free androgen index and improved clinical hyperandrogenism markers in women with PCOS, suggesting benefits beyond lipid lowering. Calcium with vitamin D is an evidence-based adjunct for metabolic features of PCOS as noted above.

Hypothyroidism and thyroid conditions

Autoimmune thyroid disease (Hashimoto's thyroiditis) is far more common in women than men, at approximately a 10:1 female-to-male ratio. Women on levothyroxine for hypothyroidism who are also taking rosuvastatin and calcium are managing three agents simultaneously. The calcium-levothyroxine interaction, not calcium-rosuvastatin, is the timing priority. Take levothyroxine 30-60 minutes before breakfast, and take calcium at a completely separate time, ideally with a meal, at least 4 hours away from levothyroxine.

Osteoporosis and bone health

Women account for approximately 80% of the 10 million Americans with osteoporosis. Some observational data suggest statins may have a positive effect on bone mineral density through inhibition of osteoclast activity, though this has not been confirmed in large randomized trials and rosuvastatin is not approved as a bone therapy. Calcium and vitamin D remain the evidence-based nutritional foundation. If you are taking a bisphosphonate alongside rosuvastatin, the only timing rule you need is for the bisphosphonate and calcium, not for rosuvastatin and calcium.

Familial hypercholesterolemia

Women with familial hypercholesterolemia (FH) may need rosuvastatin at higher doses (20-40 mg) for many years before menopause. The American Heart Association's 2018 FH scientific statement recommends that women with FH use effective contraception because statins are teratogenic, and that statin therapy be stopped as soon as pregnancy is confirmed. Calcium needs are identical to the general female population; there is no documented interaction that changes calcium management in FH specifically.

Practical Dosing and Timing Guide for Women Taking Both

The table below summarizes what actually requires timing caution in a common multi-drug regimen. Rosuvastatin is flexible on timing; it can be taken at any time of day with or without food.

| Medication | Take With | Separate From | Notes | |---|---|---|---| | Rosuvastatin (Crestor) | Any time, with or without food | Antacids (Al/Mg) by 2 hours | No food or calcium restriction | | Calcium carbonate | With a meal (needs acid) | Levothyroxine by 4+ hours; bisphosphonates by 30-60 min | Split doses if >600 mg/day | | Calcium citrate | With or without food | Levothyroxine by 4+ hours | Better for low-acid states; postmenopausal women often have reduced gastric acid | | Levothyroxine | 30-60 min before food | Calcium, iron, PPIs by 4+ hours | Take first thing in the morning | | Bisphosphonate (e.g., alendronate) | First thing in morning, with plain water only | Calcium, food by 30+ min; remain upright 30 min | Weekly dosing is typical |

One practical note: calcium citrate is absorbed equally well with or without food and does not require stomach acid, making it a better choice for postmenopausal women who may have reduced gastric acid production (achlorhydria becomes more common with age).

Splitting your calcium supplement dose into two smaller doses (for example, 500 mg twice daily rather than 1,000 mg once daily) improves fractional absorption and reduces the per-dose cardiovascular risk signal associated with large single doses.

Who This Is Right For, and Who Should Think Twice

Women who can take both without significant concern

• Postmenopausal women on rosuvastatin for LDL management who have a documented calcium gap in their diet
• Perimenopausal women with a new statin prescription who are also supplementing for bone health, provided total calcium stays at or below 1,200 mg/day from all sources
• Women with PCOS taking rosuvastatin for dyslipidemia and calcium/vitamin D for metabolic support
• Women with FH who are not pregnant or planning pregnancy and who need both agents

Women who need extra caution or individualized review

• Women taking rosuvastatin plus levothyroxine plus calcium: the levothyroxine-calcium timing rule is non-negotiable
• Women taking a bisphosphonate alongside rosuvastatin and calcium: bisphosphonate sequencing must be carefully mapped
• Women with a history of nephrolithiasis (kidney stones): high calcium supplementation can increase oxalate stone risk; dietary calcium is generally safer than supplements in this group
• Women with a prior myocardial infarction or established ASCVD who are considering high-dose calcium supplements: discuss with your cardiologist or clinician whether food-source calcium alone can meet your needs
• Women of reproductive age on rosuvastatin who are not using reliable contraception: this requires an urgent conversation with your clinician

Women for whom rosuvastatin is absolutely contraindicated

• Women who are currently pregnant
• Women who are breastfeeding (generally avoided; discuss alternatives)

Evidence Gaps: What We Do Not Know Yet

Women have been underrepresented in statin trials. The sex-specific data on rosuvastatin pharmacokinetics in perimenopause versus postmenopause (where estrogen's effect on lipid metabolism, hepatic enzyme activity, and body composition changes substantially) is limited. Most PK studies were conducted in mixed-sex populations where women were a minority. The calcium-cardiovascular meta-analyses relied predominantly on postmenopausal cohorts, so the calcium risk signal in premenopausal women is genuinely unclear.

No randomized trial has directly examined whether the timing of calcium relative to rosuvastatin changes lipid outcomes in women. The absence of a documented interaction is reassuring, but it is also partly a function of the fact that this specific question has not been the subject of a dedicated pharmacokinetic study in women across hormonal life stages. When your clinician says "there is no interaction," they are correct based on available evidence; they are not saying the question has been thoroughly studied in a diverse female population.